Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.49 |
| ▸ | CTSS | P25774 | 11/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984731 | 1.00 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL11596489 | 0.88 | CTSK (0.48) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL2130020 | 0.88 | CTSK (0.48) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL17840460 | 0.88 | CTSK (0.48) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL13019134 | 0.87 | CTSK (0.46) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL1486220 | 0.87 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL688341 | 0.87 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL3323682 | 0.87 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL30385524 | 0.86 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL4279525 | 0.86 | CTSK (0.49) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010782-A | Gelagliptin intermediate Process for the preparation of bulk compounds | 四川定科制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-2611776-B1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD (KR) | 2016-09-21 | — | — | EP | disclosed |
| CN-103080088-B | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD | 2014-09-24 | — | — | CN | disclosed |
| US-8741927-B2 | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD. (KR) | 2014-06-03 | — | — | US | disclosed |
| EP-2611776-A2 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG Life Sciences Ltd (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| CN-103080088-A | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD | 2013-05-01 | — | — | CN | disclosed |
| US-8133892-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2012030106-A2 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2012-03-08 | — | — | WO | disclosed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | CTSK 2452/4885CTSS 2351/4885CTSL 2978/4885 |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | DPP4, DPP7, DPP8 | CTSK 272/4885CTSS 437/4885CTSL 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.